Industry
Medical - Diagnostics & Research
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
Loading...
Open
45.78
Mkt cap
2.7B
Volume
834K
High
46.82
P/E Ratio
-11.92
52-wk high
60.90
Low
45.32
Div yield
N/A
52-wk low
15.85
Portfolio Pulse from Chris Katje
October 31, 2024 | 7:23 pm
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 12:28 pm
Portfolio Pulse from Benzinga Newsdesk
October 22, 2024 | 12:13 pm
Portfolio Pulse from Benzinga Insights
October 01, 2024 | 6:01 pm
Portfolio Pulse from Benzinga Newsdesk
October 01, 2024 | 5:03 pm
Portfolio Pulse from Lekha Gupta
September 15, 2024 | 11:08 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 12:37 pm
Portfolio Pulse from Benzinga Newsdesk
August 05, 2024 | 11:48 pm
Portfolio Pulse from Avi Kapoor
August 05, 2024 | 3:22 pm
Portfolio Pulse from Benzinga Newsdesk
August 05, 2024 | 2:52 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.